LOG IN

Medicenna Therapeutics Corp.

Versiunea din 18 septembrie 2024 20:11, autor: Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Medicenna Therapeutics Corp. listata cu simbolul US.MDNA ==Descriere companie== Medicenna Therapeutics Corp. (https://www.medicenna.com) is a clinical stage immunotherapy company. The Company is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional...)
(dif) ← Versiunea anterioară | Versiunea curentă (dif) | Versiunea următoare → (dif)

Pagina dedicata companiei Medicenna Therapeutics Corp. listata cu simbolul US.MDNA

Descriere companieModificare

Medicenna Therapeutics Corp. (https://www.medicenna.com) is a clinical stage immunotherapy company. The Company is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The Company has not earned any revenues from its products.

Grafic actiuni companieModificare

Ultimele stiri despre Medicenna Therapeutics Corp. (US.MDNA)Modificare

Adus de la „https://wiki.tradeville.ro/index.php?title=Medicenna_Therapeutics_Corp.&oldid=429879”